文献速递消化道肿瘤放疗放疗物理与技术

胰腺癌放疗中无意脾照射是否预测结局

Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-11-08

研究177例局部晚期胰腺癌患者接受诱导化疗后放化疗,发现放化疗后严重淋巴细胞减少(ALC<0.5 K/UL)与总生存期较差独立相关,而较高的脾脏剂量参数(MSD、V10、V15、V20)增加严重淋巴细胞减少风险,建议在计划评估时关注脾脏DVH。

要点

  • 放化疗后严重淋巴细胞减少是局部晚期胰腺癌总生存期较差的独立预测因素。
  • 较高的脾脏平均剂量和V10、V15、V20与严重淋巴细胞减少风险增加相关。
  • 临床允许时,治疗计划评估中关注脾脏剂量体积直方图可能降低严重淋巴细胞减少风险。

核心结论

  • 放化疗后严重淋巴细胞减少是接受放化疗的局部晚期胰腺癌患者总生存期较差的独立预测因素。
  • 较高的脾脏剂量增加放化疗后严重淋巴细胞减少的发生风险。

研究设计与样本

  • 回顾性分析177例局部晚期胰腺癌患者,2006年1月至2012年12月接受诱导化疗(主要为吉西他滨为基础方案)后行放化疗(中位50.4 Gy,同步卡培他滨)。
  • 记录基线、放化疗前及放化疗后2至10周绝对淋巴细胞计数,分析脾脏剂量体积直方图参数与总生存期及严重淋巴细胞减少的关系。

主要发现

  • 放化疗后中位绝对淋巴细胞计数为0.68 K/UL(范围0.13-2.72),显著低于基线1.42 K/UL(范围0.34-3.97,P<.0001)和放化疗前1.32 K/UL(范围0.36-4.82,P<.0001)。
  • 放化疗后绝对淋巴细胞计数<0.5 K/UL与较差总生存期相关:单因素分析中位总生存期11.1 vs 15.3个月(P=.01),多因素分析风险比=1.66(P=.01)。
  • 严重淋巴细胞减少患者的中位脾脏平均剂量(9.8 vs 6 Gy,P=.03)、中位V10(32.6 vs 16%,P=.04)、V15(23.2 vs 9.5%,P=.03)、V20(15.4 vs 4.6%,P=.02)显著更高。
  • 多因素分析中,诱导后淋巴细胞减少(P<.001;比值比=5.25)和脾脏平均剂量(P=.002;比值比=3.42)是放化疗后严重淋巴细胞减少的独立预测因素。

关键数值与推荐

  • 严重淋巴细胞减少定义为放化疗后绝对淋巴细胞计数<0.5 K/UL。
  • 脾脏剂量体积参数包括平均脾脏剂量和接受至少5、10、15、20 Gy照射的脾脏体积百分比(V5、V10、V15、V20)。

临床怎么用

  • 对局部晚期胰腺癌放化疗患者,关注放化疗后绝对淋巴细胞计数,严重淋巴细胞减少提示预后较差。
  • 临床允许时,在治疗计划评估中关注脾脏剂量体积直方图,可能有助于降低放化疗后严重淋巴细胞减少风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether severity of lymphopenia is dependent on radiation dose and fractional volume of spleen irradiated unintentionally during definitive chemoradiation (CRT) in patients with locally advanced pancreatic cancer (LAPC). METHODS: 177 patients with LAPC received induction chemotherapy (mainly gemcitabine-based regimens) followed by CRT (median 50.4 Gy with concurrent capecitabine) from January 2006 to December 2012. Absolute lymphocyte count (ALC) was recorded at baseline, before CRT, and 2 to 10 weeks after CRT. Splenic dose-volume histogram (DVH) parameters were reported as mean splenic dose (MSD) and percentage of splenic volume receiving at least 5- (V5), 10- (V10), 15- (V15), and 20-Gy (V20) dose. Overall survival (OS) was analyzed with use of the Cox model, and development of post-CRT severe lymphopenia (ALC <0.5 K/UL) was assessed by multivariate logistic regression with use of baseline and treatment factors. RESULTS: The median post-CRT ALC (0.68 K/UL; range, 0.13-2.72) was significantly lower than both baseline ALC (1.42 K/UL; range, 0.34-3.97; P<.0001) and pre-CRT ALC (1.32 K/UL, range 0.36-4.82; P<.0001). Post-CRT ALC <0.5 K/UL was associated with inferior OS on univariate analysis (median, 11.1 vs 15.3 months; P=.01) and multivariate analysis (hazard ratio = 1.66, P=.01). MSD (9.8 vs 6 Gy, P=.03), median V10 (32.6 vs 16%, P=.04), V15 (23.2 vs 9.5%, P=.03), and V20 (15.4 vs 4.6%, P=.02) were significantly higher in patients with severe lymphopenia than in those without. On multivariate analysis, postinduction lymphopenia (P<.001; odds ratio [OR] = 5.25) and MSD (P=.002; OR= 3.42) were independent predictors for the development of severe post-CRT lymphopenia. CONCLUSION: Severe post-CRT lymphopenia is an independent predictor of poor OS in LAPC patients receiving CRT. Higher splenic doses increase the risk for the development of severe post-CRT lymphopenia. When clinically indicated, assessment of splenic DVHs before the acceptance of treatment plans may minimize the risk of severe post-CRT lymphopenia.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chadha AS, Liu G, Chen HC, et al. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2016. PMID: 28068240. doi:10.1016/j.ijrobp.2016.10.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。